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rpL3 promotes the apoptosis of p53 
mutated lung cancer cells by down-
regulating CBS and NFκB upon 
5-FU treatment
Annapina Russo1, Assunta Saide1, Roberta Cagliani1, Monica Cantile2, Gerardo Botti2  
& Giulia Russo1
5-FU is a chemotherapy drug commonly used for the treatment of human cancers; however drug 
resistance represents a major challenge for its clinical application. In the present study, we reporte that 
rpL3 induced by 5-FU treatment in Calu-6 cells represses CBS transcription and reduces CBS protein 
stability leading to a decrease of CBS protein levels. rpL3 also regulates negatively the activation 
of NFκB by preventing NFκB nuclear translocation through IκB-α up-regulation. Furthermore, we 
demonstrate that rpL3 significantly enhances the apoptosis of 5-FU treated Calu-6 cells promoting the 
overexpression of the pro-apoptotic proteins Bax and the inhibition of the anti-apoptotic protein Bcl-2. 
We finally demonstrate that rpL3 potentiates 5-FU efficacy inhibiting cell migration and invasion. Our 
results suggest that combination of rpL3 and 5-FU is a promising strategy for chemotherapy of lung 
cancers lacking functional p53 that are resistant to 5-FU.
5-FU has been widely used against a variety of cancers including breast, skin, colorectal, liver, pancreatic and 
lung cancers1. The main mechanism responsible of 5-Fluorouracil (5-FU) activity is the inhibition of thymidylate 
synthase (TS) and subsequent incorporation of 5-FU metabolites into RNA and DNA2. It has been demonstrated 
that some ribosomal proteins (rp) are critical players in 5-FU treatment of cancer cells. Specifically, 5-FU triggers 
nucleolar stress and consequently a subset of rp including rpL5, rpL11 and rpL23 are released from ribosome to 
activate p53 by inhibiting MDM2 pathway3. In addition, we recently identified a new p53-independent but still 
rp-dependent molecular pathway activated in cell response to drug treatment. In particular, we demonstrated that 
human rpL3 acts as stress sensing molecule essential for cancer cell response to ribosomal stress caused by 5-FU 
and oxaliplatin (L-OHP) in colon and lung cancer cells lacking active p534. However, the clinical use of 5-FU is 
limited by drug resistance. In order to develop new strategies to increase 5-FU anticancer activity is important to 
identify novel genes involved in the molecular signalling pathways activated by 5-FU. These genes could offer new 
targets for chemotherapy or predictive biomarkers of response to 5-FU-based chemotherapy. Emerging evidences 
are accumulating regarding a crucial role of cystathionine-β-synthase (CBS) in promoting cellular bioenergetics, 
proliferation and migration in tumors. CBS is one of three principal enzymes involved in the biosynthesis of H2S 
in various mammalian cells and tissues5. Recent reports showed high expression levels of CBS in colon6, ovarian7, 
prostate8 and breast cancer cells9. The functional role of changes in the levels of CBS in other types of cancer has 
not been explored yet5 To our knowledge studies in lung have not been reported. CBS catalyzes the synthesis 
of cystathionine in the trans-sulfuration pathway and its expression is tightly regulated because of its critical 
role in antioxidant and methylation metabolism. Intracellular amounts of CBS are regulated by transcriptional 
and epigenetic mechanisms10. CBS activity is also regulated by post-translational modifications through a small 
ubiquitin-like modifier protein which is correlated with the localization of CBS in the nucleus leading to dimin-
ished catalytic activity. We have recently demonstrated that CBS can be phosphorylated in a PKG-dependent 
manner at Ser227 and this event lead to an increased catalytic activity11,12. Pharmacological inhibition or genetic 
silencing of CBS is associated with antitumor effects in vitro and in vivo, and enhances the efficacy of the currently 
used anticancer drugs as L-OHP13.
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Several evidence demonstrate that NFκ B is constitutively activated in a variety of solid tumors including lung 
cancer14. Activation of NFκ B occurs by release from the Iκ B molecules or by cleavage of the inhibitory ankyrin 
repeat domains of p100 and p10515. Recently, it has been demonstrated that CBS depletion enhances cisplatin 
efficacy by inhibiting NFκ B activation7.
The results of the present study led us to identify CBS and NFκ B as new molecular targets involved in cell 
response to 5-FU mediated by rpL3. We demonstrated that upon ribosomal stress induced by 5-FU, rpL3: (i) 
downregulates CBS protein levels; (ii) interacts with CBS and inhibits CBS half life; (iii) decreases NFκ B activity 
by repressing its translocation to the nucleus; (iv) upregulates Iκ B-α protein levels by preventing its degrada-
tion. We finally demonstrated that rpL3 potentiates 5-FU efficacy inducing mitochondrial apoptotic pathway and 
inhibiting cell migration and invasion. These results indicate that rpL3 could be a promising adjuvant treatment 
in improving the efficacy of 5-FU based chemotherapy of lung cancer cells lacking functional p53.
Results
CBS and rpL3 expression profile in human normal and tumor tissues. Emerging data suggest that 
CBS plays an important role in the regulation of cancer cell biology5. To evaluate CBS and rpL3 clinical significance 
in lung cancer, we employed quantitative real-time PCR (qRT-PCR) and immunoblotting to assess the expression 
of CBS and rpL3 at the mRNA and protein levels in 21 lung cancers and normal tissues. Comparison of human 
lung cancer specimens with patient-matched normal tissues revealed the up-regulation of CBS and the down-reg-
ulation of rpL3 in the cancers (Fig. 1A,B). Table 1 summarizes demographic, pathological and clinical data.
rpL3 downregulates CBS expression upon 5-FU treatment. We have recently demonstrated that 
rpL3 is essential to mediate cell response to 5-FU in Calu-6 cells4. Having established the expression profile of 
CBS and rpL3 in tumors we became interested to investigate the possible involvement of rpL3 in the control of 
CBS expression in lung cancer treatment. Thus, we firstly assessed the intracellular levels of CBS in Calu-6 cells 
upon 5-FU treatment. To this aim, Calu-6 cells were treated with 100 μ M of 5-FU for 24 h. After the treatment, 
the cells were lysated and proteins extracted analyzed by western blotting. The Fig. 2A shows that 5-FU treatment 
caused a decrease of CBS expression levels. Next, to investigate the role of rpL3, we performed analogous exper-
iments in a cell clone namely rpL3Δ Calu-6 cells in which rpL3 is stably silenced16. In these cells, 5-FU failed to 
downregulate CBS expression levels (Fig. 2A). The same behavior occurs in a second independent clone namely 
rpL3Δ aCalu-6 cells (see Supplementary Fig. S1 on line, panel A).Changes of CBS protein amounts upon alter-
ation in rpL3 expression levels and 5-FU treatment suggest that the down-regulation of CBS occurs through a 
molecular mechanism mediated by rpL3.
Since we have recently demonstrated that after drug treatment the ribosome-free rpL3 behaves as a tran-
scription factor4,16, we became interested to determine if the rpL3-mediated down-regulation of CBS protein 
levels occurred via inhibition of CBS gene transcription. To this aim, total RNA from untreated and 5-FU treated 
Calu-6 and rpL3Δ Calu-6 cells was isolated and analyzed by quantitative RT-PCR using primers specific for CBS. 
We found a strong reduction of CBS mRNA levels in Calu-6 cells treated with 5-FU. Of note, no difference in CBS 
mRNA level was found in 5-FU treated rpL3Δ Calu-6 cells (Fig. 2B). Analogous experiments were performed 
in rpL3Δ aCalu-6 cells (see Supplementary Fig. S1 on line, panel B).These data indicate that rpL3 was necessary 
for regulating CBS mRNA levels in the cell response to 5-FU. Next, to test the presence of rpL3 on CBS gene 
promoter in the response to drug exposure, Calu-6 cells, untreated or treated with 100 μ M of 5-FU for 24 h, were 
collected and subjected to Chromatin immunoprecipitation experiments by using anti-rpL3 antibodies, anti-IgG 
as negative control and anti-Sp1, a protein known to bind to the CBS promoter, as positive control.
The presence of rpL3 and Sp1 in DNA-immunoprecipitated complexes was assayed by western blotting (data 
not shown). qPCR assays on the samples were performed as previously reported17. Figure 2C shows that in 
untreated cells, rpL3 is able to bind CBS promoter. After 5-FU treatment, the binding of rpL3 on CBS promoter 
was significantly decreased compared to that observed in the control.
rpL3 binds CBS and inhibits its stability. We next investigated the possibility that rpL3 and CBS could 
associate in vivo by performing coimmunoprecipitation assays. To this aim, Calu-6 cells were treated with 100 μ M 
of 5-FU for 24 h. Then, CBS and rpL3 were specifically immunoprecipitated from cell extracts by using antibodies 
against the endogenous proteins. Immunoprecipitated proteins were separated by SDS-PAGE and the presence 
of rpL3 and CBS was investigated by western blotting in the reciprocally immunoprecipitated complexes. The 
results of these experiments showed that rpL3 and CBS were co-immunoprecipitated (Fig. 3A). A control immu-
noprecipitate obtained with anti-IgG antibodies did not give any signal when probed with anti-CBS or anti-rpL3.
To understand the significance of rpL3 and CBS interaction, the turnover of CBS was determined in Calu-6 
and rpL3∆ Calu-6 cells by cycloheximide chase. Specifically, cells were incubated with cycloheximide for various 
times (30, 60, 90, 120 min). After the incubation, cells were harvested, lysated and the level of CBS was determined 
by western blot analysis (Fig. 3B). The results demonstrated that the loss of rpL3 was associated to an increase of 
CBS half-life. All together these data indicate that rpL3 physically interacts with CBS and induces its degradation.
rpL3 regulates NFκB activation pathway upon 5-FU treatment. The NFκ B pathway regulates apop-
totic signals and has been implicated in the growth of several tumours including lung carcinoma15. Thus, to deter-
mine whether 5-FU treatment could interfere with NFκ B activity, we performed EMSA using nuclear extracts 
from Calu-6 cells cultured in the presence of 100 μ M 5-FU for 24 h. Briefly, the nuclear extracts were incubated 
with dsDNA oligonucleotides containing the NFκ B recognition site. As shown in Fig. 4A, EMSA revealed consti-
tutive binding of NFκ B transcription factor in untreated Calu-6 cells. After 24 h, 5-FU treatment inhibited NFκ B 
activation in Calu-6 cells. These data suggest that 5-FU is likely to interfere with the signalling cascade that leads 
to NFκ B activation.
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Next, to understand the molecular basis underlying NFκ B activity in these cells, we examined the role of 
rpL3 in the control of nuclear translocation of NFκ B protein after 5-FU treatment. To this aim, Calu-6 and 
rpL3Δ Calu-6 cells were treated with 100 μ M 5-FU for 24 h. Then, protein extracts from the samples were ana-
lysed by western blotting. Consistent with EMSA results, the treatment of Calu-6 cells with 5-FU resulted in a 
significant decrease of the nuclear NFκ B p65 protein (Fig. 4B). Of interest, in rpL3∆ Calu-6 cells 5-FU treatment 
failed to inhibit NFκ B translocation from cytoplasm to the nucleus.
rpL3 stabilizes IκB-α in Calu-6 cells upon 5-FU treatment. The suppressed NFκ B DNA binding 
activity could be due to a prevention of the degradation of Iκ B-α protein, which is an inhibitor of the canonical 
NF-κ B pathway, upon 5-FU treatment18. To test this hypothesis, Calu-6 and rpL3Δ Calu-6 cells were treated with 
100 μ M 5-FU for 24 h. Immunoblot analysis of cell extracts revealed significant changes (about two fold induc-
tion) in protein levels of Iκ B-α associated to a strongly reduction of pIκ B-α in 5-FU Calu-6 cells (Fig. 5A). Of 
note, this effect was not observed in 5-FU treated rpL3∆ Calu-6 cells indicating that the effect of 5-FU on Iκ B-α 
expression was specifically mediated by rpL3. In conclusion, the above results suggest that 5-FU inhibits NFκ B 
activity preventing Iκ B-α degradation in rpL3-dependent manner. To investigate the mechanism by which rpL3 
increases Iκ B-α levels, we next determined the effect of rpL3 on Iκ B-α protein stability.
The degradation of Iκ B-α was evaluated by treating Calu-6 and rpL3∆ Calu-6 cells with cycloheximide for 
different times (0, 20, 40, 60, 90 min). The results demonstrated that silencing of rpL3 was associated to a decrease 
of Iκ B-α half-life (Fig. 5B). These data indicate that rpL3 increases Iκ B-α protein stability.
Figure 1. Expression of rpL3 and CBS in the lung tumor tissues. (A) Representative western blotting of CBS 
and rpL3 protein expression in human lung cancer specimens paired with the corresponding normal tissues. 
N:non-tumor tissue. T:primary tumor tissue. Each number corresponds to a case number. β -actin was used as 
loading control. Quantification of signals is shown. **P < 0.01, *P < 0.05 vs. normal tissues set at 1. (B) qRT-
PCR data showing the expression of CBS and rpL3 mRNAs in tumor tissues. **P < 0.01, *P < 0.05 vs. normal 
tissues set at 1. Results illustrated in Figs 1–7 are representative of three independently performed experiments; 
error bars represent the standard deviation.
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Role of rpL3 in mitochondrial apoptosis upon 5-FU treatment. As previously documented, NFkB 
protein can act as survival factor by inhibiting apoptosis19 and the downregulation of CBS triggers mitochondrial 
apoptosis20. Recently, we have shown a proapoptotic function of rpL317. Starting from these findings, in order 
to investigate the factors leading to the rpL3-induced apoptosis in Calu-6 cells upon 5-FU treatment, we deter-
mined the effect of 5-FU-induced rpL3 on activities of apoptosis-related proteins of the mitochondria-mediated 
pathway. In particular, the ratio of Bcl-2/Bax was used to evaluate the occurrence and severity of apoptosis21. To 
this aim, Calu-6 cells and rpL3Δ Calu-6 cells were treated with 100 μ M 5-FU for 24 h. Then, cells were lysated and 
protein extracts were analysed by western blotting for the expression profile of Bax and Bcl-2. The Fig. 6 shows a 
marked decrease of Bcl-2 levels associated to an increase of Bax levels in Calu-6 cells treated with 5-FU compared 
with untreated cells. Of interest, these effects were not obeserved when we treated rpL3∆ Calu-6 cells with 5-FU. 
Among caspase family, which are activated when the ratio of Bcl-2/Bax is reduced, we analyzed the expression 
of caspases-3 which is a crucial regulator in the caspase-dependent cell apoptosis pathway22. As attended, the 
active caspase-3 form, which is proteolytically generated during apoptosis, was observed only in 5-FU treated 
Calu-6 cells. This data revealed that the involvement of a caspase-dependent pathway may lead to rpL3-mediated 
apoptosis.
rpL3 potentiates the citotoxic activity of 5-FU in Calu-6 cells. Our results prompted us to investigate 
whether the up-regulation of rpL3 may potentiate the cytotoxic effect of 5-FU. With the aim of examining the 
combined effect of rpL3 and 5-FU on the cell proliferation, Calu-6 cell viability was evaluated by using TMRE and 
MTT assays. Specifically, Calu-6 cells were transiently transfected with 2 μ g of pHA-rpL3 or empty vector. Then, 
cells were treated with 100 μ M 5-FU. 24 h later, modifications of mitochondrial inner membrane were estimated 
by TMRE staining and analysed by flow cytometry. As expected, rpL3 or 100 μ M 5-FU treatment induced apop-
tosis on these cells (Fig. 7A). Of note, in cells transfected with pHA-rpL3 and treated with 5-FU the cytotoxicity 
was increased of about 30% as compared with cells treated with 5-FU or rpL3 alone (Fig. 7A). As shown in Fig. 7B 
the results obtained with MTT assay were in line with those obtained with the TMRE assay.
Furthermore, we investigated the role of rpL3 overexpression alone or in combination with 5-FU on Calu-6 
cell migration and invasion. To this purpose, Calu-6 cells, transiently transfected with pHA-rpL3, treated 
or not with 100 μ M of 5-FU for 24 h, were analyzed by using Boyden chamber migration assay. As shown in 
Fig. 7C and Supplementary Fig. S2 on line, the migration ability of 5-FU treated Calu-6 cells was reduced of 
about 40% as compared with untreated cells set as 100%. When rpL3 was overexpressed, the migration ability 
of 5-FU treated Calu-6 cells was further reduced (75%) demonstrating that rpL3 overexpression was able to 
improve 5-FU-mediated inhibition of cell motility. We also examined whether rpL3 affected the invasion ability 
of Calu-6 cells. A significant decrease in invasion ability of Calu-6 cells was observed when these cells were tran-
siently transfected with pHA-rpL3 and treated with 5-FU as compared to untrasfected, 5-FU treated cells (see 
Supplementary Fig. S2). Quantification of invading cell numbers indicated that overexpression of rpL3 reduced 
the invasion ability by 80% (Fig. 7D).
All together these results strongly suggest that the ectopic expression of rpL3 allowed a more potent cytotoxic 
activity of 5-FU on lung cancer cells.
Case no. Age (years)/Sex (M/F)
Site
DiagnosisPrimary Relapse Tissue
1 77/M lung none ADCmix (signet, solid, acinar) grade III
2 59/M lung brain ADCmix (mucinous, solid) grade II
3 62/F lung none ADCmix (lepidic, acinar) grade I
4 66/M lung none ADCmix (signet, solid, lepidic) grade II
5 58/M lung none Adenosquamous grade III
6 57/M lung none ADCmix (solid, papillary, acinar) grade III
7 75/M lung none ADCmix (acinar, solid, lepidic) grade III
8 64/M lung none ADC mucinous grade II
9 64/M lung linfoma ADC solid grade III
10 57/M lung lung ADC papillary grade II
11 62/M lung na ADCmix (lepidic, acinar, solid) grade II
12 48/F lung na ADCmix (solid, acinar, papillary) grade II
13 57/M lung na ADCmix (papillary, lepidic, acinar) grade II
14 66/F lung na ADCmix (solid, signering, papillary) grade III
15 72/F lung na ADCmix (papillary, micropap, acinar) grade II
16 64/M lung na ADCmix (acinar, papillary, solid) grade II
17 33/F lung na Adenoid cystic carcinoma
18 69/F lung none Adenosquamous grade II
19 72/M lung bone ADC lepidic grade I
20 68/M lung brain Squamous grade II
21 48/M lung none ADC lepidic grade I
Table 1.  ADC: adenocarcinoma; na: not available.
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Discussion
Several evidences indicate that perturbation in the expression of rp induces the tumorigenesis23. Rp have been 
found overexpressed in cancer, for example rpL19, rpL7a, rpL37 in prostate cancer24 rpL15 and rpL19 in gastric 
cancer25,26. The expression of other rp was found reduced as rpL27, rpL37, rpL41 in a subset of cell lines derived 
Figure 2. 5-FU treatment is associated to the rpL3-mediated down-regulation of CBS at transcriptional 
level. (A) Representative western blotting of CBS protein expression. Calu-6 and rpL3Δ Calu-6 cells were 
treated with100 μ M 5-FU for 24 h. Then, protein extracts were analyzed by western blotting assay with 
antibodies against CBS and rpL3. β -actin was used as loading control. Note that shRNA-mediated silencing of 
rpL3 abolished down-regulation of CBS after 5-FU treatment. Quantification of signals is shown. **P < 0.01, 
*P < 0.05 vs. untreated cells set at 1. (B) Total RNA from Calu-6 and rpL3Δ Calu-6 cells, untreated or treated 
with 100 μ M 5-FU for 24 h, was subjected to qPCR with primers specific for CBS. Quantification of signals is 
shown. **P < 0.01, *P < 0.05 vs. untreated cells set at 1. (C) Analysis of the interaction between rpL3 and CBS 
gene promoter in response to 5-FU treatment. DNA-rpL3, DNA-Sp1 or DNA-IgG immunocomplexes from 
Calu-6 cells untreated or treated with 100 μ M 5-FU for 24 h were subjected to qPCR with primers specific for 
CBS gene promoter. Quantification of signals is shown. *P < 0.05 vs. untreated Calu-6 cells set at 1
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from nasopharyngeal carcinomas27. Changes in the expression levels of rps have been used as prognostic or 
predictive values to distinguish between normal and cancer cells. To date, increased expression of the rpL19 
accurately identifies prostatic malignancy, can discriminate the progressive form of the disease and predicts the 
biological behavior of individual prostate cancers and patient survival25. Decreased expression of rpL15 may serve 
as a prognostic marker in pancreatic ductal adenocarcinoma and was significantly associated with poor overall 
survival28.
Some rps participate the tumorigenesis by their extraribosomal functions by regulating the expression of 
oncogene and tumor suppressors.
A number of rps including rpL37, rpS15, rpS20 have been shown to bind MDM2 and inhibit its E3 ligase 
activity, leading to p53 stabilization and cell cycle arrest29.
Ribosome biogenesis is one of the major biosynthetic activities in a cancer cell and thus represents a good 
target in anticancer therapy. Different levels of perturbation of ribosome biogenesis by chemotherapeutic drugs 
have been defined, including inhibition of rRNA gene transcription, inhibition of early and late maturation of 
rRNA precursors, and perturbation linked to disintegration of nucleolar structures30.
Emerging data are accumulating about the identification of other targets in the ribosome biogenesis machin-
ery including ribosomal proteins themselves. rpS2 was reported to be a therapeutic targeting for the eradication 
of prostate cancer in preclinical tumor modeling studies31. Silencing of rpL19 abrogated the aggressive phenotype 
of human prostate cancer32.
Lung cancer represents one of the most common malignant tumors in the world and the leading cause of 
cancer-related death in many countries33. 5-FU-based combination therapies have been for a long time stand-
ard treatments; however resistance to 5-FU has been recognised as the main reason for cancer therapy failure. 
Therefore, attempts to enhance the therapeutic effectiveness of this drug are needed in order to improve patients 
Figure 3. rpL3 binds CBS and negatively affects its half-life. (A) CBS and rpL3 were specifically 
immunoprecipitated from Calu-6 cell extracts with antibodies against the endogenous CBS and endogenous 
rpL3. Immunoprecipitates were separated by SDS–PAGE and immunoblotted with antibodies versus rpL3 
and CBS. Note the absence of signal in IgG immunocomplex. (B) Calu-6 and rpL3∆ Calu-6 cells were treated 
with CHX for 30, 60, 90 and 120 min. Then, cell lysates were immunoblotted with anti-CBS and anti-β -actin 
antibodies. Quantification of signals is shown. *P < 0.05 vs. untreated Calu-6 cells set at 1
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survival. To find more appropriate therapeutic opportunities for cancer treatment, the identification of new 
molecular targets involved in cell response to 5-FU treatment may be the basis for new combination therapies. 
We have recently demonstrated that human. rpL3 acts as stress sensing molecule essential in the cell response 
to ribosomal stress caused by 5-FU in cancer cells lacking active p534,34. Specifically, we have demonstrated that 
after 5-FU treatment rpL3 is up-regulated and accumulates as ribosome free form needed to mediate 5-FU apop-
totic cell response. In fact the loss of rpL3 makes chemotherapeutic drug ineffective. We have demonstrated that 
ectopic expression of rpL3 in cancer cells induces cell cycle arrest or apoptosis by positively modulating p21 
expression at transcriptional and post-translational levels16,17. Moreover, we found that rpL3 status was associated 
to chemoresistance since the loss of rpL3 makes chemotherapeutic drugs, such as 5-FU, oxaliplatin, actinomycin 
D and cisplatin ineffective4,16,35.
It has been recently reported a functional relation between H2S and p21 expression. In particular, an increase 
of H2S amount into the cells is associated to down-regulation of p21 expression leading to cancer proliferation36. 
Furthermore, several lines of evidence from previous studies reported increased expression of CBS in various 
cancers5. In the light of these findings we hypothesized the existence of a new rpL3 mediated pathway in response 
to 5-FU treatment involving CBS. We employed qRT-PCR and immunoblotting to assess the expression of CBS at 
mRNA and protein levels respectively. We found that the expression of CBS is higher in lung tumors than in nor-
mal tissues confirming the oncogenic potency of CBS. Analysis of expression profile of rpL3 in the same tissues 
reveals that rpL3 is expressed at lower level in tumors than in normal tissues (Fig. 1). Furthermore, we demon-
strated that 5-FU treatment is associated to changes of CBS expression levels in Calu-6 cells. At 24 h of treatment, 
we observed a marked downregulation of CBS at protein and mRNA levels (Fig. 2A,B). Of note, silencing of rpL3 
abolishes these effects indicating that the alteration of CBS levels after drug treatment is rpL3-dependent. Results 
of ChIP experiments imply a negative role of rpL3 in CBS gene transcription (Fig. 2C). Analysis of immunopre-
cipitates of rpL3 in Calu-6 cells shows that rpL3 and CBS coimmunoprecipitate together indicating that these 
proteins associate in vivo (Fig. 3A). These results led us to hypothesize that the specific interaction between rpL3 
and CBS could affect CBS turnover. We demonstrated that in cell stably depleted of rpL3, the half life of CBS was 
Figure 4. 5-FU treatment inhibits NFκB DNA binding and decreases its nuclear translocation. (A) Calu-6 
cells were incubated or not with 100 μ M 5-FU for 24 h. Then, nuclear lysates were incubated with a 32P-labelled 
NFκ B consensus probe and analyzed for NFκ B DNA-binding complexes in EMSA. (B) Representative western 
blotting of NFκ B expression. Calu-6 and rpL3∆ Calu-6 cells were treated or not with 100 μ M 5-FU for 24 h. 
After the treatment, cells were subjected to fractionation to obtain the nuclear fraction (NF) and the cytosolic 
fraction (CF). Protein extracts from the samples were analyzed by western blotting with antibodies against 
NFκB. Histone H1 and LDH were used as controls for NF and CF, respectively.
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decreased (Fig. 3B). These data demonstrate that rpL3 acts as a negative regulator of CBS stability. On this basis, 
we propose that upon ribosomal stress induced by 5-FU, ribosome free rpL3 represses CBS expression acting as 
repressor of transcription and as negative regulator of protein stability. Taken together these results introduce 
rpL3 as an important player in CBS activity.
It is well established a strong correlation between cancer and inflammation37. A plausible hypothesis is that 
CBS up-regulation observed in human tumor tissues and cancer cells could be a consequence of local or systemic 
inflammation38. NFκ B is a key factor with a role as a pivotal link between inflammation and cancer39. There is 
considerable evidence that NFκ B is constitutively activated in a variety of solid tumors, including lung cancer40. 
It has been shown that 5-FU suppresses NFκ B expression in human salivary gland cancer cells41. Furthermore, 
numerous studies in cancer cells have demonstrated that inhibition of NFκ B signaling with various approaches 
increase the efficacy of chemotherapeutics in vitro and in vivo42,43.
These findings prompted us to investigate whether in condition of 5-FU treatment rpL3 status could induce 
pertubation in NFκ B signaling. Our data indicated a strong correlation between intracellular levels of rpL3 and 
the activation of NFκ B signaling (Fig. 4). In particular, our results show that rpL3 silencing induces a strong 
increase in Iκ B-α half life (Fig. 5) with consequent down-regulation of NFκ B signaling. These data together 
with recent finding demonstrating that silencing of CBS in ovarian cancer cells is associate to a decrease of NFκ 
B promoter activity7, led us to suppose that the drastic reduction in NFκ B activity, observed after 5-FU treatment 
in Calu-6 cells, is a result of rpL3 mediated CBS down-regulation and Iκ B-α stabilization. In summary, our study 
Figure 5. rpL3 prevents the degradation of IκB-α protein upon 5-FU treatment. (A) Representative western 
blotting of Iκ B-α and pIκ B-α expression. Calu-6 and rpL3Δ Calu-6 cells were treated or not with 100 μ M 
5-FU for 24 h. After the treatment, protein extracts from the samples were analyzed by western blotting with 
antibodies against Iκ B-α , pIκ B-α and β -actin as control. (B) Calu-6 cells and ∆ rpL3Calu-6 cells were treated 
with CHX for 20, 40, 60 and 90 min. Then, cell lysates were immunoblotted with anti- Iκ B-α and anti-β -actin 
antibodies. Quantification of signals is shown. *P < 0.05 vs. untreated ∆ rpL3Calu-6 cells set at 1.
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identify rpL3 as a protein that targets either CBS to destabilize it acting at transcriptional and post-translational 
levels or Iκ Bα acting at post-tanslational level with consequent reduction of NFκ B activity. Numerous studies in 
cancer cells have demonstrated that the inhibition of either NFκ B or CBS increase the efficacy of chemioterapeu-
tic drugs7,43. As a newly identified CBS and NFκ B repressor, we suggest that rpL3 could be used in association 
with 5-FU to enhance the susceptibility of lung cancer cells to this drug. In fact, we report that co-treatment of 
cells with 5-FU and pHA-rpL3 lead to a markedly increased sensitivity of cells to 5-FU. In particular, our results 
demonstrate that rpL3 strongly increase 5-FU mediated cytotoxic effect (Figs 6 and 7). In addition, when cells 
were treated with a combination of 5-FU and pHA-rpL3 we obserbed a strong reduction in cell migration and 
invasion (Fig. 7). These data indicate that rpL3 overexpression associates to a strong increase of drug cytotoxicity. 
Taking together these results show that the efficacy of 5-FU chemotherapy depends on rpL3 status. Along this 
line, the knowledge of rpL3 status in p53 null cancers may have a significant value in terms of the efficacy of 
chemotherapy based on 5-FU. Hence, the development of treatments aimed at upregulating rpL3 may be benefi-
cial for the treatment of cancers lacking p53 and downregulated rpL3.
Methods
Tissues. The research has been carried out in accordance with the Declaration of Helsinki (2013) of the 
World Medical Association. Informed consent was obtained from all 21 subjects involved in this study and all 
methods described in this section were carried out in accordance with the guidelines approved by the ethics 
committee of the National Cancer Institute ‘G. Pascale’ of Naples. Homogenization of tissues, was performed as 
Figure 6. Role of rpL3 on apoptosis. Representative western blotting of Bcl-2, Bax, procaspase-3 and clevead 
caspase-3 protein expression. Calu-6 and rpL3Δ Calu-6 cells were treated or not with 100 μ M 5-FU for 24 h. 
After the treatment, protein extracts from the samples were analyzed by western blotting with indicated 
antibodies. Quantification of signals is shown. **P < 0.01, *P < 0.05 vs. untreated Calu-6 cells set at 1.
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previously reported44. Total RNA was extracted once from the tissue samples by using an ultrapure TRIzol reagent 
(GibcoBRL, Carlsbad, CA, USA) and used in three independent experiments.
Cell cultures, DNA, transfections and drug treatments. Calu-6 cells, rpL3Δ Calu-6 and 
rpL3Δ α Calu-6 derived from Calu-6 cell line and stably silenced for rpL316, were cultured in Dulbecco’s Modified 
Figure 7. Role of rpL3 on cell viability, migration and invasion upon 5-FU treatment. Calu-6 cells were 
transiently transfected with pHA-rpL3 and treated with 100 μ M 5-FU for 24 h or untreated. Then, cell viability 
was evaluated using the (A) TMRE and (B) MTT assays. (C) Overexpression of rpL3 inhibits cell migration 
upon 5-FU treatment. Calu-6 cells were transiently transfected with pHA-rpL3 and treated with 100 μ M 5-FU 
for 24 h or untreated. Then migration of cells were examined using Boyden chamber. (D) Overexpression of 
rpL3 inhibits cell invasion of fibronexin matrix by Calu-6 cells upon 5-FU treatment. Invasion of cells through 
fibronexin matrix was examined using Boyden chamber. Quantification of signals is shown, **P < 0.01 vs. 5-FU 
treated Calu-6 cells.
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Eagle’s Medium (DMEM) with glutamax (Invitrogen, Carlsbad, California) supplemented with 10% fetal bovine 
serum (FBS), 2 mM L-glutamine, penicillin-streptomycin 50 U/ml and 0.5 μ g/ml puromycin (Sigma-Aldrich).
Drug treatments were performed by adding to cells 100μ M 5-FU for 24 h. Transfection of pHA-rpL3 plasmid 
was performed in cells using Lipofectamin 2000 as previously described45.
Realtime PCR. Total RNA was isolated from cells using RNeasy Plus Mini kit (QIAGEN). RNA was first 
retrotranscribed as previously reported44 and then realtime PCR was carried out using TaqManH SYBR Green 
Master Mix (Applied Biosystems). The primers for human CBS (PPH13484B-200) and β actin (PPH00073G-200 
ACTB) were from QIAGEN. The comparative Ct method was used to calculate the relative abundance of the 
mRNA and compared with that of β -actin expression46,47.
Chromatin immunoprecipitation. Chromatin immunoprecipitation assay was performed as previously 
reported16. The sequence for primers used to amplify CBS promoter were: Forward 5′-CGCCCCTCTT 
TTCCATGTATCCGTCCAG-3′ and Reverse 5′ -ACCTGGCATT- GGTGGGCGTCCTCACA-3′.
Immunoprecipitation and western blotting. Immunoprecipitation assay was performed as previuosly 
reported45. Calu-6 whole cell lysate (1 mg) was incubated with 30 μ l of protein A/G agarose beads coated with 
5 μ g of anti-CBS (Santa Cruz Biotechnology) or anti-rpL3 (Primm, Milan, Italy), at 4 °C for 12 h. The eluted 
proteins were loaded on 12% SDS-PAGE and detected by western blotting. Aliquots of protein samples (30 μ g) 
were resolved by 12% SDS-gel electrophoresis and transferred into nitrocellulose filters. The proteins were visu-
alized with enhanced chemiluminescence detection reagent according to the manufacturer’s instructions (Pierce, 
Rockford, Illinois).
Western blotting analysis was performed as previously reported48. The membranes were challenged with 
anti-rpL3 (Primm, Milan, Italy), anti-CBS, anti-NFκ B, anti-Iκ B-α , anti-pIκ B-α and anti-β -actin (Santa Cruz 
Biotechnology). Proteins were visualized with enhanced chemiluminescence detection reagent according to the 
manufacturer’s instructions (Pierce, Rockford, Illinois).
Protein half-life analynsis. Cells were treated with Cycloheximide (CHX,Sigma-Aldrich, St. Louis, MO, 
USA) 0,1 mg/ml for different times, and subsequently harvested and lysed using RIPA lysis buffer (50 mM 
Tris-HCl pH 7.4, 1% NP40, 0,5% Na-deoxycolate, 150 mM NaCl, 1 mM Na3VO4, 1 mM NaF, 1X EDTA-free 
Roche protease inhibitor cocktail). Protein extracts from samples were analyzed by western blotting.
Preparation of nuclear extracts and electrophoresis mobility shift assay. Nuclear extracts was 
performed as previously reported49,50, EMSA assay was performed as previously reported51.
Mitochondrial membrane potential measurement. To quantify changes in mitochondrial membrane 
potential cells were labeled with 50 nM of the mitochondrial membrane potential-sensitive fluorescent dye TMRE 
(Invitrogene) for 30 mi a 37 °C, analyzed by a Cyan-ADP Flow Cytometer (DAKOCytomation) and quantified 
using Summit software.
MTT assay. MTT assay was performed as previously described52.
Boyden chamber migration and invasion. Starved Calu-6 and rpL3∆ Calu-6 cells (1 × 105 cells) were 
plated into transwell chamber in serum free D-MEM medium. The lower chambers of the plate were supplied 
with D-MEM medium supplemented with 10% FBS. Then migration of cells was examined using Boyden cham-
ber. 24 h after indicated treatments cells were fixed and stained with crystal violet and counted under microscope. 
For cell invasion assay Boyden chamber equipped with membranes precoated with fibronectin were used53.
Statistical analysis. Error bars represent mean ± s.d. from n = 3 biological replicates. *P < 0.05 was consid-
ered significant, **P < 0.01 was considered highly significant; Student t-test is used throughout.
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